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Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat
advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent
response and improved performance status. Recently, pro-inflammatory cytokines, such as regulated upon
activation normal T cell expressed and secreted (RANTES), interleukin (IL)-10 and IL-8 have been proposed as
mediators of cancer development. EGFR-TKIs have been found to affect this network of pro-inflammatory cytokines.
Methods: EGFR-TKIs (erlotinib, 150 mg/day; and gefitinib, 250 mg/day) were administered once per day. Treatment
was continued until disease progressed or the patient developed intolerable symptoms of toxicity, or withdrew
his/her consent for study participation. The treatment was a part of standard care. We investigated the correlation
between plasma pro-inflammatory cytokines (including plasma RANTES, IL-10, and IL-8) levels and clinical outcomes
following EGFR-TKI treatment in lung cancer patients. Pro-inflammatory cytokine levels were evaluated at diagnosis
and on treatment day 30 after the first administration of EGFR-TKIs.
Results: Overall, 33 patients were enrolled. Plasma pro-inflammatory cytokine levels were determined for all
patients at diagnosis. Plasma samples from 26 patients were obtained on treatment day 30. High level of RANTES at
diagnosis was associated with severe general fatigue (P = .026). Low level of RANTES at diagnosis was significantly
associated with long-term survival (P = .0032). Percent decrease change of IL-10 was associated with severity of rash
(P = .037). The plasma IL-8 level on treatment day 30 (median, 5.48 pg/mL; range, 0.49–26.13 pg/mL) was
significantly lower than the level at diagnosis (median 10.45 pg/mL; 3.04–54.86 pg/mL; P = .021).
Conclusions: These results suggest that EGFR-TKIs may suppress systemic inflammation and promote tumor
shrinkage. The network of pro-inflammatory cytokines was affected by EGFR-TKI treatment for NSCLC. In addition,
the clinical outcomes of EGFR-TKI treatment were influenced by the status of the plasma pro-inflammatory
cytokines at diagnosis.
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Cancer is associated with systemic inflammation driven
by multiple pro-inflammatory cytokines [1]. The network
of pro-inflammatory cytokines such as regulated upon ac-
tivation normal T-cell expressed and secreted (RANTES),
interleukin (IL)-10, and IL-8 have been proposed as medi-
ators of cancer development [1,2]. Pro-inflammatory cyto-
kines play roles in catabolism, gluconeogenesis, and
acute-phase protein production [1]. They also play pro-
tective roles during the first stages of inflammation; how-
ever, persistent continuation has deleterious effects.
Gefitinib and erlotinib are orally administered epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) used for the treatment of non–small-cell lung can-
cer (NSCLC) in patients with activated mutations of the
EGFR gene [3-6]. Unlike treatment with cytotoxic agents,
EGFR-TKIs are associated with excellent response rates,
prolonged survival, low numbers of adverse hematological
events, and improved quality of life. EGFR signaling is
triggered by the binding of EGF and EGF-like growth fac-
tors, resulting in the homodimerization of EGFR mole-
cules or heterodimerization of EGFR with other closely
related receptors such as c-erbB2 [7]. EGF-stimulated
EGFR phosphorylation [8] promotes cancer cell prolifera-
tion through the downstream phosphoinositide 3-kinase
(PI3K)/Akt and extracellular signal-regulated kinase
(ERK1/2) pathways [9]. PI3K/Akt and ERK1/2 pathways
are activated in lung cancer [10] and are closely associ-
ated with cancer cell proliferation [11,12].
RANTES is a known chemotactic cytokine that is pro-
duced by many cell types, including T-lymphocytes, mono-
cytes, platelets, eosinophils, epithelial cells, dendritic cells,
and mast cells [13]. RANTES, which is transcribed and se-
creted not only by T cells, other inflammatory cells, and
stromal cells, but also tumor cells and nonmalignant bron-
chial epithelium, is involved in immunoregulatory and in-
flammatory processes [14]. RANTES has been used as a
prognostic indicator in both breast and cervical cancers
and high levels of RANTES in these malignancies corre-
lates with a poor outcome [14,15]. RANTES in breast car-
cinoma is associated with invasion, metastasis, and poor
clinical survival [16,17]. Protein kinases C (PKC) α and β
have been shown to affect tumor progression and malig-
nant phenotype [18,19]. PKCα plays an obligatory role in
EGFR transactivation and signaling to ERK1/2 activation
[20-22]. PKCα-dependent EGFR transactivation may con-
tribute to the development and maintenance of the
androgen-refractory phenotype in advanced prostate can-
cer [22]. PKCα/β activator 12-O-tetradecanoylphorbol-13-
acetate (TPA) only induces IL-8 expression, whereas both
inhibit tumor necrosis factor (TNF)-α induced RANTES
expression [2].
IL-10, an immunoregulatory component in the cytokine
network, is mainly expressed by monocytes, macrophages,T cells, and normal and neoplastic B cells [23]. IL-10 is as-
sociated with tumor malignancy via immune escape. IL-10
promotes tumor malignancy by promoting T cell apop-
tosis and tumor cell survival [24]. Marked decrease
in plasma IL-10 levels accompanies marked increase
in RANTES levels in patients with severe, treatment-
resistant atopic dermatitis [25]. Previous reports have
shown that IL-10 has different prognostic significance in
early and late stage lung cancer patients [23]. Absence of
IL-10 expression is associated with poor outcome in stage
I NSCLC, whereas presence of IL-10 positive macrophages
in late stage NSCLC is an indicator of poor prognostic
outcome. Moreover, persistence of EGFR and IL-10 in the
blood of colorectal cancer patients after surgery indicates
a high risk of relapse in patients [26].
IL-8 is a cytokine of the CXC chemokine family and
acts as a ligand for 2 G-protein coupled receptors [7]. In
addition to its role in neutrophil recruitment and activa-
tion, IL-8 is thought to be involved in a wide variety of
other processes such as angiogenesis and the formation
of metastases in lung cancer [27,28]. EGF has been dem-
onstrated to initiate the release of IL-8 from bronchial
epithelial and lung cancer cells [9,29,30]. ERK phosphor-
ylation is associated with IL-8 expression in airway epi-
thelium cells [31,32]. An in vitro study has shown that
the ability of IL-8 to increase cell proliferation is blocked
by an inhibitor of EGFR tyrosine kinase [7]. IL-8 is posi-
tively regulated by EGFR signaling, whereas EGFR in-
hibitors block IL-8 expression [33]. In the nude mice
model, treatment with monoclonal antibody C225, di-
rected against the EGFR, inhibits mRNA and protein
production of IL-8 [34].
EGFR-TKIs are thought to partially affect these cancer
related pro-inflammatory cytokine networks. To test
this hypothesis, we investigated the correlation between
plasma pro-inflammatory cytokine levels and clinical
outcomes following EGFR-TKI treatment in lung cancer
patients. Pro-inflammatory cytokine levels were evalu-




Eligible patients had pathologically confirmed advanced
NSCLC that recurred after 1 or 2 prior chemotherapies.
Each patient was required to meet the following criteria:
adequate organ function, performance status (PS) of 0–2,
and no other active malignancies. Mutations in the tyro-
sine kinase domain (exons 18–21) of EGFR were identified
using the peptide nucleic acid (PNA) clamp polymerase
chain reaction (PCR) assay [35]. Written informed consent
was obtained from all patients. This study was approved
by the Osaka City University Institutional Review Board
(approval number: 1377).
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EGFR-TKIs (erlotinib, 150 mg/day; and gefitinib,
250 mg/day) were administered once per day. Treatment
was continued until disease progressed or the patient de-
veloped intolerable symptoms of toxicity, or withdrew
his/her consent for study participation. The treatment
was a part of standard care. The objective responses of
each lesion examined were assessed every 4 weeks fol-
lowing commencement of EGFR-TKIs administration
by using the Response Evaluation Criteria in Solid Tu-
mors, version 1.0 [36]. Toxicity was graded according
to the National Cancer Institute Common Toxicity
Criteria Version 3.0 [37]. EGFR-TKIs related non-
hematologic toxicities of grade 3 and 4 were managed by
reducing the dose of EGFR-TKIs. The progression-free
survival (PFS) or overall survival (OS) was calculated from
the start of EGFR-TKI treatment to the date of disease
progression or death.Table 1 Patient characteristics (n = 33)
Characteristics Number
Age, years














Median (range) 370 (0–3840)
Body mass index, Kg/m2








EGFR, Epidermal growth factor receptor; Ad, Adenocarcinoma; Sq, Squamous
cell carcinoma, La, Large-cell carcinoma; Ex, Exon; del, Deletion.Analyses of plasma pro-inflammatory cytokines
Plasma samples were collected at diagnosis and on treat-
ment day 30. Venous blood (7 mL) was collected in
EDTA (anticoagulant)-containing tubes and immediately
centrifuged at 3000 rpm for 15 min. Plasma samples
were frozen at −80°C until analysis. Plasma RANTES,
IL-10, and IL-8 levels were measured using the Luminex
200× PONENT system (Milliplex MAP kit; Millipore,
Billerica, MA, USA), according to the manufacturer’s in-
structions. Plasma RANTES, IL-10, and IL-8 levels were
estimated as previously reported [38]. Briefly, 25 μL of
plasma was incubated with antibody-linked beads over-
night at 4°C, rinsed twice with the washing solution, and
incubated for 1 hour with biotinylated secondary anti-
bodies. Data acquisition using the Luminex system was
performed after a final incubation with streptavidin-
phycoerythrin for 30 minutes. The minimum detectable
concentrations of plasma RANTES, IL-10, and IL-8
levels were 69.00, 21.50, and 13.25 pg/mL, respectively.
All samples were assayed in duplicate.
Statistical analyses
All values are expressed as the median and range. Statis-
tical comparisons of pro-inflammatory cytokine levels
before and after treatments were performed using the
Wilcoxon signed-ranks test. The association between the
plasma pro-inflammatory cytokine levels at diagnosis
and the effects of EGFR-TKI treatments was assessed
using the Mann-Whitney test. The association between
the changes of plasma pro-inflammatory cytokine levels
and the effects of EGFR-TKI treatments was also
assessed with Mann–Whitney test. Stepwise multiple
regression analysis was performed to evaluate the inde-
pendent relationship of overall survival with age, sex, stage
IIIb or IV, EGFR mutation status, plasma RANTES, IL-10,
and IL-8 levels at diagnosis. Two-tailed P values <0.05
were considered significant. A box plot provides informa-
tion about the median, variability, and outliers of data dis-
tribution. The horizontal line within each box indicates
the sample median. The plot consists of a box that ex-
tends from the 25th quantile to the 75th quantile. The
box lines that extend from each end to the outermost
data point that falls within the distances were computed
as follows: 1st quartile +1.5* (interquartile range) and
3rd quartile +1.5* (interquartile range). Data points out-
side these computed ranges were considered outliers.
All statistical analyses were carried out using the JMP 8.0
statistical program (SAS Institute, Inc., Cary, NC, USA).
Results
Patient characteristics
Thirty-three patients were enrolled between September
2008 and October 2009. Adequate plasma samples could
not be obtained for analyses from 7 patients on treat-
Table 2 Summary of plasma pro-inflammatory cytokines levels at diagnosis in patients with NSCLC
Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 (ng/mL) IL-10 (ng/mL) RANTES (pg/ml)
1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2
2 Ad Ex21 L858R 0 erlotinib PR 3.33 94.2 1.41
3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13
4 Ad Ex21 L858R 0 gefitinib PR 3.92 18.1 1.85
5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11
6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56
7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02
8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38
9 Ad negative 400 erlotinib SD 34.9 3.39 3.66
10 Ad negative 0 erlotinib SD 27.1 4.94 2.25
11 Ad unknown 1800 erlotinib SD NE NE NE
12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98
13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66
14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5
15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7
16 La negative 2080 erlotinib SD NE NE NE
17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06
18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82
19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783
20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02
21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76
22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91
23 Sq unknown 1560 erlotinib PD NE NE NE
24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57
25 Ad unknown 0 erlotinib PD NE NE NE
26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12
27 Ad unknown 1410 erlotinib PD NE NE NE
28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89
29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16
30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292
31 Ad negative 825 erlotinib PD 8.27 1.59 2.13
32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7
33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06
NSCLC, Non-small-cell lung cancer; Ad, Adenocarcinoma; Sq, Squamous cell carcinoma; La, Large-cell carcinoma; Ex, Exon; del, Deletion; PR, Partial response; SD,
stable disease; PD, Progression disease; IL-8, Interleukin-8; IL-10, Interleukin-10; RANTES, Regulated upon activation normal T-cell expressed and secreted.
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patients, negative in 9, and unknown in 5. Initially, none
of the patients with EGFR mutations had the secondary
T790M mutation. The numbers of patients with con-
comitant diseases and drugs, which influence cytokine
levels, were as follows: chronic rheumatoid arthritis (1),
diabetes mellitus (6), hyperlipidemia (6), and hyperten-
sion (17). No patient had an infectious disease. The pa-
tient population profile is provided in Table 1.Clinical outcomes
The rate of rash, diarrhea, appetite loss, general fa-
tigue, and liver dysfunction of all grades was 97.0%,
30.3%, 48.5%, 50.0%, and 38.5%, respectively. Response
to EGFR-TKI treatments included partial response
(PR) in 8 cases (24%), stable disease (SD) in 14 (42%),
and progressive disease (PD) in 11 (33%). Patients in
all of 8 PR cases, 8 of 14 SD cases, and 3 of 11 PD




Figure 1 Association of plasma interleukin (IL)-10 and
regulated upon activation normal T cell expressed and
secreted (RANTES) levels with epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) toxicity. (a) Plasma RANTES
levels at diagnosis show significant correlation with the severity of
general fatigue (P = .025). (b) Percent decrease change of IL-10 was
associated with severity of rash (P = .037).
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PD (4 patients) and side effects (3 patients: grade 3 drug-
induced pneumonitis in 1 patient and grade 3 diarrhea
in the other 2 patients). The median PFS and OS were
102 days (6–1442 days) and 255 days (70–1447 days),
respectively.
Clinical features associated with pro-inflammatory
cytokine levels
First, we analyzed the association between pro-
inflammatory cytokine levels at diagnosis and patient
characteristics (Table 2). High levels of plasma IL-8
at diagnosis showed significant positive associations
with the Brinkman index (P = .0063). No significant
associations were observed between plasma IL-10 or
RANTES levels and other patient characteristics at
diagnosis. Second, we analyzed the association betweenpro-inflammatory cytokine levels at diagnosis and adverse
effects observed following EGFR-TKI treatment. High
level of plasma RANTES at diagnosis was associated with
the severity of general fatigue (P = .025, Figure 1a). Percent
decrease change of plasma IL-10 was associated with se-
verity of rash (P = .037, Figure 1b). Third, we analyzed the
association between pro-inflammatory cytokine levels at
diagnosis and the clinical efficacy of the EGFR-TKI treat-
ment. EGFR mutations, sex, and low level of plasma
RANTES at diagnosis were significantly associated with
long-term survival (P = .0044, .037, and .046, respectively).
In a multivariate logistic regression model, EGFR muta-
tions, sex, and low level of plasma RANTES at diagnosis
were identified as significantly positive prognostic factors
(R2 = .26, P = .004; R2 = .43, P = .037; R2 = .52, P = .045, re-
spectively) (Table 3). No significant associations were ob-
served between plasma pro-inflammatory cytokine levels
at diagnosis and treatment responses.
Plasma pro-inflammatory cytokine levels before and after
EGFR-TKI treatment
To examine the effect of EGFR-TKI treatment on the
network of pro-inflammatory cytokines, we analyzed
pro-inflammatory cytokine levels in the 26 patients
still receiving treatment on day 30. The plasma IL-8
(5.48 pg/mL; range, 0.49–26.13 pg/mL) level on treat-
ment day 30 was significantly lower than the level
at diagnosis (10.45 pg/mL; range, 3.04–54.86 pg/mL;
P = .021) (Figure 2). The plasma levels of other pro-
inflammatory cytokines at diagnosis, including IL-10
(2.16 pg/mL; range 0.69–125.8 pg/mL) and RANTES
(2.08 ng/mL; range 0.29–3.66 ng/mL), showed no sig-
nificant change on treatment day 30.
Discussion
We demonstrated that pro-inflammatory cytokines were
affected by EGFR-TKI treatment for NSCLC. High level
of plasma RANTES at diagnosis was associated with the
severity of general fatigue. Low level of plasma RANTES
at diagnosis was significantly associated with long-term
survival by univariate and multivariate analyses. Percent
decrease change of plasma IL-10 was associated with the
severity of rash. Decreased level of plasma IL-8 was ob-
served after EGFR-TKI treatment.
Tumor-derived RANTES has been detected in many
clinical specimens [15]. In our study, high level of
plasma RANTES at diagnosis was associated with the se-
verity of general fatigue. Low level of plasma RANTES
at diagnosis was significantly associated with long-term
survival. Thus, patients with high systemic inflammation,
as represented by RANTES, may experience severe gen-
eral fatigue and shorter survival time. Moran et al. found
a correlation between increased RANTES expression
and tumor lymphocytic response in lung cancer patients
Table 3 Step-wise multiple regression analysis between
overall survival and clinical parameters
Variable Standardized regression
coefficient
F P value Change
in R2
Age - 0.042 0.840 0.604
Sex -108.81 4.883 0.037 0.431
EGFR mutation
status
-164.64 9.954 0.004 0.258
Stage - 1.093 0.307 0.604
IL-8 level at
diagnosis
- 0.001 0.973 0.604
IL-10 level at
diagnosis
3.30 3.726 0.066 0.584
RANTES level
at diagnosis
-0.15 4.453 0.045 0.517
EGFR, Epidermal growth factor receptor; IL-8, Interleukin-8; IL-10, Interleukin-10;
RANTES, Regulated upon activation normal T-cell expressed and secreted.
Figure 2 Comparison of the plasma interleukin (IL)-8 levels
before and after epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) treatment. The IL-8 (5.48 pg/mL;
range, 0.49–26.13 pg/mL) levels on treatment day 30 were
significantly lower than levels at diagnosis (10.45 pg/mL; range,
3.04–54.86 pg/mL; P = .021).
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with improved survival in patients with early stage
NSCLC [16]. The clinical stage of our patients was ad-
vanced, with 6 patients showing stage III and 27 showing
stage IV. This may explain the completely different re-
sults of Moran et al. [17].
The determinants of tumor response and survival were
assessed in patients treated with EGFR-TKIs. The multi-
variate Cox proportional hazards model showed that
time since diagnosis and good performance status were
significant predictors of survival, and survival correlated
with the occurrence and severity of rash [6]. Other re-
ports show that mutations in the EGFR are predictive
and prognostic indicators in patients with NSCLC
treated with erlotinib [39] and gefitinib [40]. In our
study, the significant prognosis factors in the multivari-
ate analysis were EGFR mutation status, sex, and plasma
RANTES, not PS. Patient eligibility in this study re-
quired a threshold criteria of PS 0/1. Therefore, the
small number of PS 2 may be the reason why PS was
not a significant prognostic factor in the multivariate
analysis.
Skin toxicity is the most frequently encountered toxicity
in patients treated with EGFR-TKIs, and it is believed to
result from direct interference of the drug function and
EGFR signaling in the skin [41]. EGFR is expressed in the
basal layer of the epidermis. Roles of EGFR include stimu-
lation of epidermal growth, inhibition of differentiation,
and acceleration of wound healing [41]. Inhibition of mito-
gen activated protein kinase (MEK), a downstream effector
in the EGFR pathway, also leads to papulopustules, sug-
gesting a mechanism-based effect. Similar inflammatory
events may also account for periungual inflammation and
onycholysis, whereas abnormalities in keratinocyte differ-
entiation may explain impaired stratum corneum leading
to xerosis and pruritus [42]. A recent report showed thatthe macrophage inflammatory protein (MIP)-1β levels are
significantly lower in patients with skin toxicity compared
to the levels in patients with no skin toxicity [43]. In atopic
dermatitis, a marked increase in plasma RANTES levels
accompanied by a marked decrease in IL-10 levels is ob-
served [25]. Suppression of Th1 cells by Th2 cells seems to
be abrogated by decreased IL-10 and Th2 cytokines, which
may be mediated through elevated RANTES in patients
with severe atopic dermatitis. In our study, percent de-
crease change of plasma IL-10 was associated with the se-
verity of rash. Therefore, immune responses mediated by
MIP-1β and plasma IL-10 may play a role in the healing
process of keratinocytes damaged by EGFR-TKIs.
In our study, EGFR-TKI treatment suppressed tumor
proliferation and improved PS and quality of life. At the
molecular level, EGFR inhibitors suppress EGFR phos-
phorylation and inhibit the downstream signals of PKC
and ERK, which are associated with IL-8. As a result,
EGFR-TKI treatment decreased plasma IL-8 levels. We
previously reported that increased adiponectin and de-
creased insulin levels are observed after EGFR-TKI treat-
ment [44]. This circumstance may improve cancer related
anorexia. Our 2 results suggest that EGFR-TKIs may im-
prove cancer cachexia as a consequence of tumor shrink-
age and suppress cancer related systemic inflammation.
Our study has certain limitations. The number of pa-
tients enrolled was small, and we did not evaluate the dif-
ferences between the effects of cytotoxic agents and
EGFR-TKIs on pro-inflammatory cytokines. The relation-
ship between the concentrations of pro-inflammatory
cytokines and tissue immunoreactivity remains to be
elucidated.
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High level of plasma RANTES at diagnosis was associ-
ated with the severity of general fatigue. Low level of
plasma RANTES at diagnosis was significantly associated
with long-term survival by univariate and multivariate
analyses. Percent decrease change of plasma IL-10 level
was associated with the severity of rash. Decreased plasma
IL-8 level was observed after EGFR-TKI treatment. The
network of pro-inflammatory cytokines was affected by
EGFR-TKI treatment for NSCLC. In addition, the clinical
outcomes of EGFR-TKI treatment were influenced by the
status of the plasma pro-inflammatory cytokines at diag-
nosis. Our study may provide useful information regarding
patient outcomes after EGFR-TKI treatment. A large clin-
ical trial is required to clarify these results.
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